RLMD
Relmada Therapeutics Inc.
Latest News for RLMD
Mizuho Securities analyst Uy Ear reiterated a Buy rating on Relmada Therapeutics yesterday and set a price target of $19.00. Ear covers the Healthc......
Relmada Therapeutics Inc (($RLMD)) has held its Q4 earnings call. Read on for the main highlights of the call. Relmada Therapeutics’ latest earning......
The latest announcement is out from Relmada Therapeutics ( ($RLMD) ). Relmada Therapeutics reported audited fourth-quarter and full-year 2025 resul......
Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. The Phase 3 study titled “A Phase 3 Study of NDV-01 as an Int......
Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. The Phase 3 study titled “A Phase 3 Study of NDV-01 as an Int......
Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. The BOOST study, officially titled “A Phase 3, Randomized Stu......
Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. The BOOST study, officially titled “A Phase 3, Randomized Stu......
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gain Therapeutics (GANX – Research Report) and Relma......
Investors seeking the top stock market stories for Monday will want to check out the daily wrap-up. ...
News data is sourced from MarketXLS API and updated regularly.
Showing 9 of 9 articles.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RLMD | $6.97 | +3.2% | 458.55K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Relmada Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW